HEALTHJul 8 · 06:00 UTCSCMP WORLDJulie Zhang

China’s biotech firms challenge US with rapidly developing RAS-targeted cancer therapies

Chinese biotech firms are developing RAS-targeted cancer therapies that challenge U.S. companies like Revolution Medicines, whose drug improved survival for pancreatic cancer patients. Analysts note Chinese rivals are undervalued despite rapid progress in this competitive field.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Revolution MedicinesorganizationChinese biotech firmsorganizationRAS-targeted cancer therapiestopicpancreatic cancertopicinvestment banksorganizationscientistsperson

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 1 · 13:30 UTC
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
SCIENCEJun 23 · 12:06 UTC
China rapidly catching up with US in biotech
HEALTHMay 26 · 08:30 UTC
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
HEALTHJun 2 · 08:58 UTC
Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation
HEALTHMay 14 · 11:00 UTC
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million